A Phase 3, multicenter, randomized, double-blind, 48-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized high-risk participants with COVID-19
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
Outpatient CTRC
Principal Investigator
Thomas Campbell, MD
Study ID
Protocol Number: 22-0587
More information available at ClinicalTrials.gov: NCT05305547
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers